Next Generation Cancer Diagnostics Market Size to Garner $29.7 billion by 2028 with 17.80% CAGR: Latest Industry Insight by Markets N Research

Key players in the next generation cancer diagnostics market include Agilent Technologies, Inc., Abbott, BD, OPKO Health, Inc., F. Hoffmann-La Roche Ltd, GENERAL ELECTRIC COMPANY, Illumina, Inc, QIAGEN, BioGenex, Siemens Healthcare GmbH, bioMérieux SA, NeoGenomics Laboratories, Inc., Telerad Tech, BioNTech SE, Thermo Fisher Scientific Inc, Hologic Inc., Koninklijke Philips N.V., PerkinElmer Inc, Cepheid.

Chicago, Nov. 10, 2022 (GLOBE NEWSWIRE) -- The report "Next Generation Cancer Diagnostics Market by Technology (NGS, LOAC, RT-PCR) Application (CTC, Biomarker), Cancer Type (Lung, Breast) – Global Forecast to 2028" states that Next Generation Cancer Diagnostics Market is projected to grow from USD 11.1 billion in 2021 and is projected to reach USD 29.7 billion by 2028; it is expected to grow at a CAGR of 17.80% from 2022 to 2028. The demand for next-generation cancer diagnostic tests is predicted to increase with the prevalence of oncology disorders.

These tests are anticipated to aid in the early detection of cancer and enable effective prognosis, which in turn is anticipated to positively impact the development of this vertical during the projected year. A key element anticipated to open up profitable growth opportunities for this market is the development and introduction of product offerings by numerous large companies. Potentially high-value growth avenues and opportunities characterize the market during the forecast period due to the growing development of companion diagnostics for their deployment in delivering personalized and advanced genomic therapy.

Download PDF Brochure:

Browse in-depth TOC on "Next Generation Cancer Diagnostics Market"

264 – Tables
98– Figures
350 – Pages

Drivers, Restraints, Opportunities in Next Generation Cancer Diagnostics Market:

Drivers: Increasing cancer cases
Restraints: Lack of skilled professionals
Opportunities: Increase in the geriatric population

Next Generation Cancer Diagnostics Market Report Scope:

Report CoverageDetails
Forecast Period2022 to 2028
Forecast Period 2022 to 2028 CAGR17.80%
2028 Value ProjectionUSD 29.7 billion
Base Year2021
Market Size in 2021USD 11.1 billion in 2021
Historical Data for2018 to 2021
Purchase Direct ReportBuy Now

Enquiry Before Buying @

Segmentation of Global Next Generation Cancer Diagnostics Market-

Global Next Generation Cancer Diagnostics Market – By Technology

  • NGS
  • LOAC
  • RT-PCR

Global Next Generation Cancer Diagnostics Market – By Application

  • CTC
  • Biomarker

Global Next Generation Cancer Diagnostics Market – By Cancer Type

  • Lung
  • Breast

The NGS category in the next generation cancer diagnostics market is expected to be the fastest-growing segment during the forecast period

The NGS segment is projected to grow the fastest during the forecast period. The benefits include finding gene duplications or deletions and identifying mutations using melting curve analysis. It is expected that NGS-based technology will become more popular, which will limit the use of DNA and protein microarrays. The growing acceptance of this technique among research organizations has been facilitated by technological developments in NGS systems, the creation of supportive library preparation standards, and the development of data analysis tools.

Lung cancer category of the next generation cancer diagnostics market to record the highest CAGR from 2022 to 2028

Lung cancer is expected to account for the highest CAGR of the next generation cancer diagnostics market from 2022 to 2028 due to the segment's relatively higher number of research initiatives and patent filings. Additionally, lung cancer has the highest occurrence worldwide, necessitating a higher market share to serve the enormous patient population. However, because of increased incidence rates that will increase the demand for diagnostic and screening technologies, breast oncology problems are predicted to experience significant growth throughout the projected period.

Click Here to Access a Free Sample Report of the Global Next Generation Cancer Diagnostics Market @

Top Next Generation Cancer Diagnostics Companies:

  • Agilent Technologies Inc.
  • Abbott
  • BD
  • OPKO Health Inc.
  • F. Hoffmann-La Roche Ltd
  • Illumina Inc
  • BioGenex
  • Siemens Healthcare GmbH
  • bioMérieux SA
  • NeoGenomics Laboratories Inc.
  • Telerad Tech
  • BioNTech SE
  • Thermo Fisher Scientific Inc
  • Hologic Inc.
  • Koninklijke Philips N.V.
  • PerkinElmer Inc
  • Cepheid

Recent Developments

  • In January 2022, Agendia, Inc., a leading provider of precision oncology for breast cancer, announced a multi-year collaboration to co-develop diagnostic (IVD) assays for oncology testing.
  • In January 2022, Boehringer Ingelheim and Illumina Inc. joined together to speed the development of precision medicines and select therapies for patients with advanced cancer.
  • In October 2021, Roche released the AVENIO tumor tissue CGP kit to enable access to personalized cancer research.

Read More Insight @

Regional Insights:

Europe is anticipated to grow at a significant rate in next generation cancer diagnostics market share from 2022 to 2028

Europe is the fastest-growing region in the next generation cancer diagnostics market. The increasing incidence of cancer cases in Europe clearly demands early detection and diagnosis of cancer. Researchers are consistently working to discover novel cancer diagnosis methods with minimal invasion. There are approximately 375000 cases of cancers detected each year, with a mortality rate of over 44%. An expanding number of researchers, the presence of top-tier research organizations, and pharmaceutical industry giants are all contributing to the advancement of cancer diagnostics research in the U.K. In addition, the COVID-19 epidemic has significantly increased public awareness of early cancer diagnosis and treatment over the past few years. The market for next-generation cancer diagnostics in the UK is strongly driven by this trend.

Get 10% Free Customization on this Report:

Browse Related Reports:

e-Pharma Market
Digital Health Market
Sterilization Equipment Market
Oxygen Therapy Market
Immunoassay Market

About Markets N research

When it comes to investing and money matters, you need the leading market research consultancy firm to help you make the right decisions during the toughest business questions and decisions. Markets N Research is the leading research company offering both tactical and strategic support to all our customers. Customer satisfaction is our goal and that is why, we have a team of skilled and experienced specialist with the ability to do data mining, information management, and revenue enhancement solutions to ensure that our clients make informed decisions when coming to investing in the market.

Markets N Research team is comprised of well skilled and equipped personnel ready to concur any upcoming challenges in the market sector for both individual people and organization around the world. We know time is money, and therefore we ensure we solve your problem within the shortest time possible to prevent delays or missing any opportunities. We use globally accepted techniques with a little innovation from our staff in solving all your market research related challenges.

Contact Us:
Markets N research
US: +1-773-649-1529

Contact Data